Skip to main
MIST
MIST logo

MIST Stock Forecast & Price Target

MIST Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Milestone Pharmaceuticals Inc. demonstrates a strong potential for growth due to the positive results from its clinical trials for etripamil, particularly regarding patient-reported outcomes such as symptom relief and treatment satisfaction, which showed statistically significant improvements. The favorable results, including high scores on the TSQM-9 effectiveness domain and global satisfaction, suggest a promising acceptance of etripamil among patients with cardiovascular conditions. Furthermore, the belief in the manageability of challenges identified in the CRL indicates that the company is positioned for future approval, enhancing its long-term outlook for investors.

Bears say

Milestone Pharmaceuticals has faced significant regulatory and clinical setbacks that have adversely impacted investor confidence in the company's stock. These challenges, coupled with a heightened diligence bar for funding in the current market environment, contribute to a negative outlook on the stock's potential for recovery. Moreover, the possibility of market competition undermining demand for etripamil and future candidates poses further risk to projected revenues.

MIST has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Milestone Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Milestone Pharmaceuticals Inc (MIST) Forecast

Analysts have given MIST a Buy based on their latest research and market trends.

According to 2 analysts, MIST has a Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Milestone Pharmaceuticals Inc (MIST)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.